JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 85 filers reported holding JOUNCE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.75 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $5,000 | -66.7% | 2,334 | +3.7% | 0.00% | – |
| Q1 2022 | $15,000 | -85.8% | 2,250 | -82.3% | 0.00% | – |
| Q4 2021 | $106,000 | +231.2% | 12,678 | +196.4% | 0.00% | – |
| Q3 2021 | $32,000 | +166.7% | 4,278 | +140.6% | 0.00% | – |
| Q2 2021 | $12,000 | -71.4% | 1,778 | -56.9% | 0.00% | – |
| Q1 2021 | $42,000 | +61.5% | 4,128 | +9.8% | 0.00% | – |
| Q2 2020 | $26,000 | -25.7% | 3,760 | -48.9% | 0.00% | – |
| Q1 2020 | $35,000 | -69.6% | 7,361 | -44.2% | 0.00% | -100.0% |
| Q4 2019 | $115,000 | +1542.9% | 13,195 | +488.8% | 0.00% | – |
| Q3 2019 | $7,000 | -69.6% | 2,241 | -51.4% | 0.00% | – |
| Q2 2019 | $23,000 | -77.7% | 4,607 | -72.3% | 0.00% | -100.0% |
| Q1 2019 | $103,000 | +10200.0% | 16,647 | +9200.0% | 0.00% | – |
| Q4 2018 | $1,000 | -99.6% | 179 | -99.6% | 0.00% | -100.0% |
| Q3 2018 | $276,000 | +3842.9% | 42,479 | +7378.7% | 0.00% | – |
| Q4 2017 | $7,000 | – | 568 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 572,829 | $1,340,000 | 100.00% |
| TRV GP III, LLC | 1,148,780 | $2,688,000 | 1.17% |
| COWEN AND COMPANY, LLC | 3,647,430 | $8,535,000 | 0.82% |
| Octagon Capital Advisors LP | 1,400,000 | $3,276,000 | 0.56% |
| Deep Track Capital, LP | 4,259,653 | $9,968,000 | 0.46% |
| PFM Health Sciences, LP | 4,094,488 | $9,581,000 | 0.35% |
| RTW INVESTMENTS, LP | 5,106,341 | $11,949,000 | 0.28% |
| Omega Fund Management, LLC | 275,513 | $645,000 | 0.24% |
| Monarch Partners Asset Management LLC | 228,370 | $534,000 | 0.16% |
| Orbimed Advisors | 2,928,900 | $6,854,000 | 0.13% |